Natco Pharma gets CDSCO nod for Semaglutide, to launch in March

Natco Pharma has received the Central Drugs Standard Control Organisation’s (CDSCO) approval to manufacture and market generic Semaglutide injection in India.

Semaglutide is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. The company will launch the product in the India market in March, Natco said in a filing on Saturday.

Earlier this week members of Natco leadership team at an investor call, on the December quarter results, said the company is positive about Semaglutide launch though the market is expected to be extremely competitive in view of several generics.

For the India market, Natco will outsource the production to a fill finish source. The company will supply all the raw materials and the source will convert them into the product. Besides launching its own brand, Natco will be also outsourcing the product to two other entities.